Radiation oncologist @InstitutBergonié
Bordeaux, France
Joined September 2020
- Tweets30
- Following61
- Followers44
- Likes124
Huck constance retweeted
New IBCG consensus:
Optimal Management of Muscle-invasive Bladder Cancer: Recommendations from the International Bladder Cancer Group
(IBCG)
Full text: authors.elsevier.com/a/1mf5C…
@shilpaonc @AndreaNecchi @UrogerliMD @PGrivasMDPhD @FaltasLab @pjhensley11 @siadaneshmand @niyatilobo @mouwlab @karima_oualla @UroMoschini @BogdanaSchmidt @AStenzl @JoshMeeks @DrRosenbergMSK #OncSurgery
Huck constance retweeted
Using individual patient data we found strong evidence of benefit across endpoints: PFS, radiographic PFS (rPFS), and castration resistance free survival (CRFS). Overall survival (OS) barely missed significance with P=0.051 in the mixed effect model
Huck constance retweeted
Examining guidelines on radiotherapy for #BladderCancer with carcinoma in situ. @ConstanceHuck joins @UroDocAsh to examine whether carcinoma in situ should contraindicate trimodality therapy for muscle-invasive bladder cancer. The conversation highlights how historical data showing poor outcomes with CIS may be outdated, as older studies used split-course radiotherapy and inferior imaging techniques. #WatchNow on UroToday to learn more > bit.ly/4pVb8NA
Huck constance retweeted
"On ne ressent aucune douleur" : qu'est-ce que la #radiothérapie #stéréotaxique, cette méthode innovante qui soigne les #cancers masculins ? #CancerDeLaProstate @ConstanceHuck @Achard_Verane #CancerDeLaVessie #MedPhys #RadOncNews | #hcsmeufr @scoopit sco.lt/9GmoC0
Commented in EUO on RAMPP trial:
• 💊 Limited modern systemic Tx
• 🔍 Stage-migration with PSMA PET
• ⏸️ Early stop → underpowered CSM signal
• ⚠️ Higher morbidity vs RT
➡️ 🎯 RT remains the most evidence-based local option in oligometastatic HSPC.
@ConstanceHuck, @AlbertoBossial
⚠️RAMPP trial :
🔑 If Local control of the primary tumor is beneficial, The optimal modality remains undefined!
🔑 RT currently represents the evidence-based, less morbid SOC until randomized data demonstrate otherwise
sciencedirect.com/science/ar…
Huck constance retweeted
Adjuvant radiotherapy evaluated for high-risk #BladderCancer after cystectomy. @VedangMurthy @TataMemorial joins @l_ballas @CedarsSinai presenting BART trial results, demonstrating adjuvant pelvic radiotherapy benefits for high-risk post-cystectomy bladder cancer patients. #WatchNow > bit.ly/4nnHFLb
Huck constance retweeted
🧪 Progress for bladder-sparing in MIBC:
An international consensus standardizes clinical complete response (cCR) and endorses event-free survival (EFS) as the key endpoint for next-gen perioperative trials.
#BladderCancer @JCO_ASCO
ascopubs.org/doi/abs/10.1200…
Huck constance retweeted
What the best approach for BCG-unresponsive NMIBC ?
If you are worried about the expenses like Donald Trump or @MRoupret, think about Radiation Therapy like @Achard_Verane !! #focus2025
Huck constance retweeted
GU005 allowed hotspots of 38.7 Gy. PACE-B allowed hotspots of 48-50 Gy.
So there is a 13 Gy eqd2 difference even between prescription doses and even more when accounting for hotspots.
Thus GU005 had a bit more BCR but lower tox. PACE-B had a little better BCR and more tox.
Just dose
Huck constance retweeted
💥Phase III BART trial (n=153) in locally advanced #BladderCancer after cystectomy + chemo:
🔹 RT (n=77) vs Obs (n=76)
🔹2-yr locoregional recurrence: 8% RT vs 26% Obs (p=0.006)
🔹OS trend ↑RT (68% vs 57%), not sig
🔹No ↑ severe late adverse events
👉Adjuvant RT ↑ control & DFS, esp T3/4 & N+ pts. #ASTRO25 #RadOnc
Huck constance retweeted
#astro25
@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.
Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased
3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.
Goodbye WPRT
Huck constance retweeted
✨Our '' rising '' star, @ConstanceHuck
discussing TMT in the context of CIS, with @UroDocAsh.
👂Listen this excellent discussion here @urotoday
following the paper published in @EUplatinum
urotoday.com/video-lectures/… – at Talence, France
Huck constance retweeted
📫 Interim results of #Sunrise4 are released @TheLancetOncol
Neoadjuvant #TAR200 + cetrelimab vs cetrelimab monotherapy in pts with #MIBC
✅ TAR200+CET: pCR 42%, Major path Response 60%
✅ in cT2 pts baseline: pCR 48%
✅ TAR200 exposure-response association: pCR 50% if TAR200x4 full cycles
Can we cure selected pts with MIBC with intravesical Rx + single agent IO?
Future: is there a way to avoid #radicalcystectomy by consolidating Response with TAR200 in selected pts?
Primary results with full biomarker results are awaited
@Larvol @ASCO @myESMO @OncoAlert @urotoday @Medscape @SanRaffaeleMI @MyUniSR @JNJNews @spsutkaMD @DrFelixGuerrero @evanguelosx @BenjaminPradere
#bladdercancer #clinicalresearch #MedTwitter #neoadjuvant
thelancet.com/journals/lanon…
Huck constance retweeted
✍️🇫🇷
SFRO: FRENCH GUIDELINES FOR THE ROLE OF RADIOTHERAPY IN THE MANAGEMENT OF BLADDER CANCER
@SFjROfr
sciencedirect.com/science/ar… – at Bordeaux, France
🚨 MUST READ 🚨
🔥 Bladder preservation with CIS? Time to rethink the rules.
👉 New in EUO: sciencedirect.com/science/ar…
🙏 Grateful to the amazing team!
#BladderCancer #Urology #RadiationTherapy #BladderPreservation #CIS
Huck constance retweeted
How to manage gynecomastia with ARPIs monotherapy?
A review by @nassimVibert 🙏
sciencedirect.com/science/ar…
#ProstateCancer #Prostate #life – at Puteaux, France
Huck constance retweeted
📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence.
🚨Meta-analysis of 43 studies (n=8,119)
⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb!
➡️link shorturl.at/unfn5
Huck constance retweeted
EAU Guidelines Update: European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines by Antoine G. van der Heijden et al
Read the full update here: buff.ly/DFOK4dt
#UroSoMe #MedTwitter #EurUrol #EAUGuidelines #GuidelinesUpdate
New insights on SBRT in recurrent ovarian cancer – now in CTRO:
“SBRT in recurrent oligometastatic ovarian cancer: An EORTC Y-ECI GCG systematic review”
👉 doi.org/10.1016/j.ctro.2025.…
🎯 Local control
⏳ Delayed systemic therapy
⚖️ Personalized strategy
@EORTC
Huck constance retweeted
📢 STORM trial breaking results at #ESTRO25!
🧪 MDT vs ENRT+MDT for nodal oligorecurrent PCa.
🧬 ENRT+MDT:
✅ Superior bRFS (57% vs 41%, p=0.014)
✅ Superior pelvic control (lrRFS 85% vs 62%, p=0.006)
✅ Superior MFS (76% vs 63%, p=0.06)
❌ No increase in ≥G2 GU/GI toxicity
